Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Article
PubMed
Google Scholar
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68.
Article
PubMed
Google Scholar
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.
Article
CAS
PubMed
Google Scholar
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.
Article
CAS
PubMed
Google Scholar
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1.
Article
PubMed
PubMed Central
Google Scholar
Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T, Satoh S, Nanjo H, Tsuchiya N, Mitsuzuka K, et al. Radical prostatectomy with and without Neoadjuvant Chemohormonal pretreatment for high-risk localized prostate Cancer: a comparative propensity score matched analysis. Clin Genitourin Cancer. 2019;17(1):e113–22.
Article
PubMed
Google Scholar
Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5:5548.
Article
CAS
PubMed
Google Scholar
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate Cancer. Curr Oncol Rep. 2017;19(2):13.
Article
PubMed
PubMed Central
Google Scholar
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transla Androl Urol. 2015;4(3):365–80.
Google Scholar
Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–80.
Article
CAS
PubMed
Google Scholar
Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and Cancer. Cell. 2015;163(4):811–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim MH, Kim J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci. 2017;74(8):1457–74.
Article
CAS
PubMed
Google Scholar
Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun. 2015;6:8126.
Article
PubMed
Google Scholar
Lai CJ, Lin CY, Liao WY, Hour TC, Wang HD, Chuu CP. CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling. Cells. 2019;8(4):295.
Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, et al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016;15(1):70.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 2002;62(22):6606–14.
CAS
PubMed
Google Scholar
Hartel A, Didier A, Pfaffl MW, Meyer HH. Characterisation of gene expression patterns in 22RV1 cells for determination of environmental androgenic/antiandrogenic compounds. J Steroid Biochem Mol Biol. 2003;84(2–3):231–8.
Article
CAS
PubMed
Google Scholar
Narita S, Tsuchiya N, Saito M, Inoue T, Kumazawa T, Yuasa T, Nakamura A, Habuchi T. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Prostate. 2008;68(3):321–35.
Article
CAS
PubMed
Google Scholar
O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10:126.
Article
CAS
PubMed
PubMed Central
Google Scholar
Saupe M, Rauschenberger L, Preuss M, Oswald S, Fussek S, Zimmermann U, Walther R, Knabbe C, Burchardt M, Stope MB. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity. World J Urol. 2015;33(10):1481–6.
Article
CAS
PubMed
Google Scholar
Liu CY, Yu T, Huang Y, Cui L, Hong W. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer. J Biol Chem. 2017;292(22):9420–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharifi N. Steroid receptors aplenty in prostate cancer. N Engl J Med. 2014;370(10):970–1.
Article
CAS
PubMed
Google Scholar
Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbo-Jorgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One. 2015;10(2):e0116691.
Article
PubMed
PubMed Central
CAS
Google Scholar
Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Castoria G. Estrogens and their receptors in prostate Cancer: therapeutic implications. Front Oncol. 2018;8:2.
Article
PubMed
PubMed Central
Google Scholar
Song R, Gu D, Zhang L, Zhang X, Yu B, Liu B, Xie J. Functional significance of hippo/YAP signaling for drug resistance in colorectal cancer. Mol Carcinog. 2018;57(11):1608–15.
Article
CAS
PubMed
Google Scholar
Liu H, Du S, Lei T, Wang H, He X, Tong R, Wang Y. Multifaceted regulation and functions of YAP/TAZ in tumors (review). Oncol Rep. 2018;40(1):16–28.
CAS
PubMed
PubMed Central
Google Scholar
Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T, Wang C, Wei W, Ke B, Yan B, Niu Y, et al. In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene. 2015;34(21):2764–76.
Article
CAS
PubMed
Google Scholar
Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y, et al. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015;35(8):1350–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.
Article
CAS
PubMed
Google Scholar
Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 2008;99(11):1849–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. Int J Mol Sci. 2016;17(1):138.
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Holden JK, Cunningham CN. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors. Cancers (Basel). 2018;10(3):81.
Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grullich C, Jager D, et al. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urol Oncol. 2018;36(4):161.e119–30.
Article
CAS
Google Scholar
Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007;117(7):1876–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, et al. Impact of therapy on genomics and Transcriptomics in high-risk prostate Cancer treated with Neoadjuvant Docetaxel and androgen deprivation therapy. Clin Cancer Res. 2017;23(22):6802–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bergstrom CP, Ruffell B, Ho CM, Higano CS, Ellis WJ, Garzotto M, Beer TM, Graff JN. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates. Anti-Cancer Drugs. 2017;28(1):120–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim D, Gregory CW, French FS, Smith GJ, Mohler JL. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol. 2002;160(1):219–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–40.
Article
CAS
PubMed
Google Scholar
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 2014;9(3):e92714.
Article
PubMed
PubMed Central
CAS
Google Scholar
Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181(6):2188–201.
Article
CAS
PubMed
Google Scholar
Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel. Cancer Biol Ther. 2011;11(2):204–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Codony-Servat J, Marin-Aguilera M, Visa L, Garcia-Albeniz X, Pineda E, Fernandez PL, Filella X, Gascon P, Mellado B. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate. 2013;73(5):512–21.
Article
CAS
PubMed
Google Scholar
Kim HJ, Park YI, Dong MS. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays. Toxicol in Vitro. 2006;20(7):1159–67.
Article
CAS
PubMed
Google Scholar
Bradley CA. AR-V7 - repress to impress. Nat Rev Urol. 2019;16(5):269.
Article
PubMed
Google Scholar